Approval · Notice of Compliance 602 · 2002
CRIXIVAN: Notice of Compliance 602
Issued July 4, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 602
- Date
- July 4, 2002
- Company
- Merck Frosst Canada & Cie, Merck Frosst Canada & Co.Kirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: use in hiv-infected pediatric patients; revised formulation of the 100mg capsules
- Therapeutic class
- Hiv protease inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CRIXIVAN | Not yet assigned | — |
Medicinal ingredients
- INDINAVIR SULFATE 100 MG per CAP
- INDINAVIR SULFATE 200 MG per CAP
- INDINAVIR SULFATE 300 MG per CAP
- INDINAVIR SULFATE 400 MG per CAP